Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


Scientists who conducted research into how physical activity impacts depression and sleep in people with MS found a positive effect on their physiological function and sleep.

There is...

Roche, the makers of ocrelizumab have today announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for the use of ocrelizumab in adults with active...

Drug company Celgene recently announced results from two phase III trials evaluating the efficacy and safety of the drug ozanimod and is now seeking approval from the U.S Food and Drug...

NHS Chief, Simon Stevens has announce that NHS England has struck a deal to make an innovative treatment for multiple sclerosis (MS) routinely available on the NHS.

From the 10 November...

A study led by the University of Sydney's Brain and Mind Centre and Royal Prince Alfred Hospital has revealed unique molecules in the blood of people with multiple sclerosis (MS) that could become...

Scientists conducting research into important MS markers have discovered that MS patients born from a caesarean delivery and receiving artificial lactation are more likely to experience the onset...

A study has shown a significant correlation between the intake of saturated fatty acids and disability and fatigue in MS patients.

The study consisted of 126 patients diagnosed with MS (84...

While most people with MS develop neurological impairments over time it is clear that some do not. This has been termed benign MS. Its existence and definition are often debated, so researchers...

Pharmaceutical company Novartis has released the full results of a phase III Paradigms study investigating the safety and efficiency of Gilenya (fingolimod) vs. interferon beta-1a in children and...

European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is recommending further restrictions on the use of the multiple sclerosis (MS) drug Zinbryta (daclizumab)...

Pages

Live Chat Software by Click4Assistance UK